Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIP and Alanine Glucagonotropic Effects in Healthy Men
NCT06419686Phase 1Recruiting
- Sponsor
- Gentofte Hospital
- Start
- Jan 2024
- Primary completion
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of glucose-dependent insulinotropic polypeptide[1-42] and l-alanine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Gentofte Hospital. Primary endpoint: Plasma concentrations of Glucagon. Started Jan 2024; status: recruiting.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]l-alanine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06419686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419686.